Brandon Cieniewicz
0000-0003-3268-7444
Publication & Citation Trends
Publications
0 total
First-In-Human Clinical Experience with CER-1236, a First-In-Class TIM-4–Based Phagocytic CAR-T Therapy, Including Platelet Transfusion Independence In an Index Patient with High-Risk MDS/AML (inv(3)/Mecom)
Cited by 0
Semantic Scholar
202 CER-1236, an investigational T cell product targeting TIM-4 Ligand, exhibits sustained effector function and resistance to exhaustion
Cited by 0
Semantic Scholar
First-in-human study of autologous chimeric engulfment receptor T-cell CER-1236 targeting TIM-4-l in acute myeloid leukemia (CertainT-1).
Cited by 1
Semantic Scholar
POSTER: AML-795 First-in-Human Study of Autologous Chimeric Engulfment Receptor T Cell CER-1236 Targeting TIM-4-L in Acute Myeloid Leukemia (CertainT-1)
Cited by 0
Semantic Scholar
AML-795: First-in-Human Study of Autologous Chimeric Engulfment Receptor T Cell CER-1236 Targeting TIM-4-L in Acute Myeloid Leukemia (CertainT-1)
Cited by 0
Semantic Scholar
363 TIM-4-L expression on ovarian cancer can be targeted by engineered chimeric engulfment receptor T cells without toxicity OA
Cited by 0
Semantic Scholar
Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentation OA
Cited by 6
Semantic Scholar
Research Topics
CAR-T cell therapy research
(16)
Immune Cell Function and Interaction
(11)
Galectins and Cancer Biology
(6)
Viral-associated cancers and disorders
(5)
Cytomegalovirus and herpesvirus research
(5)
Affiliations
University of Richmond
Institute for Stem Cell Biology and Regenerative Medicine
Rapt Therapeutics (United States)
Stanford Medicine
3DT Holdings (United States)